Immunotherapy articles within Nature

Featured

  • Article
    | Open Access

    Tumour-derived prostaglandin E2, signaling through its receptors EP2 and EP4, is shown to restrain the responses of tumour-infiltrating stem-like TCF1+CD8+ T lymphocytes, and modulation of T cell EP2 and EP4 can restore anticancer immunity.

    • Sebastian B. Lacher
    • , Janina Dörr
    •  & Jan P. Böttcher

  • Article
    | Open Access

    The transcription factor FOXO1 has a key role in human T cell memory, and manipulating FOXO1 expression could provide a way to enhance CAR T cell therapies by increasing CAR T cell persistence and antitumour activity.

    • Alexander E. Doan
    • , Katherine P. Mueller
    •  & Evan W. Weber

  • Review Article |

    This Review explores in detail the complexity of NK cell biology in humans and highlights the role of these cells in cancer immunity.

    • Eric Vivier
    • , Lucas Rebuffet
    •  & Valeria R. Fantin

  • Article |

    Single-cell transcriptomics studies on human and mouse non-small cell lung cancer and conditional knockout mouse models show that IL-4 from bone marrow basophils drives the development of granulocyte-monocyte progenitors to myeloid cells that suppress antitumour immunity.

    • Nelson M. LaMarche
    • , Samarth Hegde
    •  & Miriam Merad

  • Article |

    A CRISPR–Cas9 screen in a tumour mouse model identifies CD300ld as a tumour receptor on polymorphonuclear myeloid-derived suppressor cells and in vivo experiments indicate that it is a promising target for cancer immunotherapy.

    • Chaoxiong Wang
    • , Xichen Zheng
    •  & Min Luo

  • Article
    | Open Access

    Imaging mass cytometry is used to map the multicellular dynamics of immune checkpoint blockade-treated triple-negative breast cancer, finding that key proliferative fractions and cell–cell interactions drive response, and immunotherapy distinctively remodels tumour structure.

    • Xiao Qian Wang
    • , Esther Danenberg
    •  & H. Raza Ali

  • Article
    | Open Access

    Epitope engineering of donor haematopoietic stem/progenitor cells endows haematopoietic lineages with selective resistance to CAR T cells or monoclonal antibodies, without affecting protein function or regulation, enabling the targeting of genes that are essential for leukaemia survival and reducing the risk of tumour immune escape.

    • Gabriele Casirati
    • , Andrea Cosentino
    •  & Pietro Genovese

  • Perspective |

    The rationale behind chimaeric antigen receptor T cell therapy is reviewed, and current challenges in oncology, preliminary reports in noncancerous diseases and relevant emerging technologies are discussed.

    • Daniel J. Baker
    • , Zoltan Arany
    •  & Carl H. June

  • Perspective |

    This Perspective reviews advances in the understanding of the intersection between the DNA damage response and the response to immune checkpoint blockade therapy, and discusses how developments in the field could lead to improved anti-cancer therapies.

    • Anand V. R. Kornepati
    • , Cody M. Rogers
    •  & Tyler J. Curiel

  • Article |

    A mouse model expressing T cell antigens in the skin epidermis is used to demonstrate that local self-tolerance is maintained by PD-1, which prevents terminal CD8 T cell differentiation, effector molecule secretion and access to antigen-expressing cells.

    • Martina Damo
    • , Noah I. Hornick
    •  & Nikhil S. Joshi

  • Article
    | Open Access

    This article describes a mechanism through which CD4+ T cells can eradicate MHC-deficient tumours that escape direct CD8+ T cell targeting and thereby complement the activity of CD8+ T cells and natural killer cells to advance cancer immunotherapies.

    • Bastian Kruse
    • , Anthony C. Buzzai
    •  & Thomas Tüting

  • Article |

    Effective anti-PD-1 immunotherapy is associated with the presence of polyclonal CD8+ T cells in the tumour and blood specific for a limited number of immunodominant mutations, which are recurrently recognized over time.

    • Cristina Puig-Saus
    • , Barbara Sennino
    •  & Antoni Ribas

  • Article
    | Open Access

    CD62L+ precursors of exhausted T cells retain long-term proliferative potential, multipotency and repopulation capacity, and the transcription factor MYB is essential for the development and function of this population of cells.

    • Carlson Tsui
    • , Lorenz Kretschmer
    •  & Axel Kallies

  • Article
    | Open Access

    Synthetic chimeric orthogonal IL-2 receptors that incorporate the intracellular domain of receptors for other γ-chain cytokines such as IL-9 can reroute orthogonal signalling and alter the phenotype of T cells to improve anti-tumour responses.

    • Anusha Kalbasi
    • , Mikko Siurala
    •  & K. Christopher Garcia

  • Article
    | Open Access

    Complementary single-cell approaches show that a population of regulatory T cells co-expressing ICOS and IL-1 receptor type 1 is highly enriched in tumours but not in site-matched inflamed non-malignant tissue.

    • Florian Mair
    • , Jami R. Erickson
    •  & Martin Prlic

  • Article
    | Open Access

    A study using a mouse solid tumour model suggests that adjusting the dosing frequency of the PI3Kδ inhibitor AMG319 in the treatment of human cancers could decrease tumour growth with fewer adverse effects.

    • Simon Eschweiler
    • , Ciro Ramírez-Suástegui
    •  & Christian H. Ottensmeier

  • Article
    | Open Access

    A clinical study shows that immunotherapy with anti-HIV-1 antibodies maintains prolonged viral suppression after anti-retroviral treatment is discontinued and affects the size and composition of the intact but not the defective proviral reservoir.

    • Christian Gaebler
    • , Lilian Nogueira
    •  & Michel C. Nussenzweig

  • Article
    | Open Access

    Results in the CheckMate 649 phase 3 trial for first-line combined nivolumab and chemotherapy treatment continue to show clinically meaningful efficacy in gastric, gastro-oesophageal junction or oesophageal adenocarcinoma after 24 months, with no new safety signals.

    • Kohei Shitara
    • , Jaffer A. Ajani
    •  & Yelena Y. Janjigian

  • Article |

    Infusion of CD19-directed chimeric antigen receptor T cells into two patients with chronic lymphocytic leukaemia resulted in complete tumour remission and persistence of the infused cells more than ten years later.

    • J. Joseph Melenhorst
    • , Gregory M. Chen
    •  & Carl H. June

  • Article
    | Open Access

    Single-cell RNA sequencing and T cell receptor sequencing are combined to identify transcriptional programs specific to mutation-associated neoantigen-specific T cells in non-small cell lung cancers treated with anti-PD-1, providing insights into resistance to PD-1 blockade.

    • Justina X. Caushi
    • , Jiajia Zhang
    •  & Kellie N. Smith

  • Article |

    The bispecific IgG1-like CoV-X2 prevents SARS-CoV-2 spike binding to ACE2, neutralizes SARS-CoV-2 and its variants of concern, protects against disease in a mouse model, whereas the parental monoclonal antibodies generate viral escape.

    • Raoul De Gasparo
    • , Mattia Pedotti
    •  & Luca Varani

  • Article
    | Open Access

    In hepatocellular carcinoma driven by non-alcoholic steatohepatitis, aberrant T cell activation and impaired immune surveillance seem to make hepatocellular carcinoma less responsive to anti-PD1 or anti-PDL1 immunotherapy.

    • Dominik Pfister
    • , Nicolás Gonzalo Núñez
    •  & Mathias Heikenwalder

  • Article
    | Open Access

    A phase 1 clinical trial provides evidence that a vaccine against mutant IDH1 is safe and produces a T helper immune response in patients with glioma.

    • Michael Platten
    • , Lukas Bunse
    •  & Wolfgang Wick

  • Article |

    Results of an exploratory interim analysis from a phase I trial show that an RNA vaccine targeted towards four melanoma-associated antigens produces durable objective responses in patients with melanoma that are accompanied by strong CD4+ and CD8+ T-cell immunity.

    • Ugur Sahin
    • , Petra Oehm
    •  & Özlem Türeci

  • Article |

    After taking up tumour-associated antigens, dendritic cells in mouse and human tumours upregulate a regulatory gene program that limits dendritic cell immunostimulatory function, and modulating this program can rescue antitumor immunity in mice.

    • Barbara Maier
    • , Andrew M. Leader
    •  & Miriam Merad

  • Article |

    Chimeric antigen receptor (CAR) T cells engineered to overexpress the canonical AP-1 transcription factor c-Jun are resistant to T cell exhaustion, and provide enhanced therapeutic benefit in mouse tumour models.

    • Rachel C. Lynn
    • , Evan W. Weber
    •  & Crystal L. Mackall

Browse broader subjects

Browse narrower subjects

Browse Immunotherapy across other nature.com journals